

Appl. No. : 10/665,975
Filed : September 18, 2003

REMARKS

Restriction to one of the following groups was required under 35 USC 121:

Group I Claims 1-4, 7 and 8, drawn to a method of enhancing apoptosis of neoplastic cells, classified in class 514, subclass 2;

Group II Claims 5 and 6, drawn to a compound that inhibits the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin classified in class 530, subclass 389.2;

Group III Claims 9 and 10, drawn to a compound that inhibits Survivin in the presence of HBXIP, classified in class 530, subclass 389.4;

Group IV Claims 11-13 and 19-34, drawn to a method for identifying an agent that alters the association of Survivin and HBXIP, classified in class 435, subclass 5;

Group V Claims 14 and 17, drawn to a method for identifying an agent that inhibits the activity of Survivin, classified in class 435, subclass 5;

Group VI Claims 15, 16 and 18, drawn to a method for identifying an agent that inhibits the activity of HBXIP, classified in class 435, subclass 5.

In response to this restriction requirement, Applicant elects group III, that is claims 9 and 10.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 11, 2006

By:



Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

2280392
011106